Merck Returns Heplisav To Dynavax After FDA Rules Vaccine Too Risky For Healthy Adults
This article was originally published in The Pink Sheet Daily
Executive Summary
Regulators offer option to proceed with the hepatitis B vaccine in kidney disease patients, but can the company bear the risk/cost burden of going it alone until it can repartner?